Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study

BACKGROUND: Bacillus coagulans MTCC 5856 has been marketed as a dietary ingredient, but its efficacy in diarrhea predominant irritable bowel syndrome (IBS) condition has not been clinically elucidated till date. Thus, a double blind placebo controlled multi-centered trial was planned to evaluate the...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Nutr J
Autors principals: Majeed, Muhammed, Nagabhushanam, Kalyanam, Natarajan, Sankaran, Sivakumar, Arumugam, Ali, Furqan, Pande, Anurag, Majeed, Shaheen, Karri, Suresh Kumar
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2016
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4769834/
https://ncbi.nlm.nih.gov/pubmed/26922379
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12937-016-0140-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars